Payment overview · 2025
General Payments
$52.04
3 reported records · 2 companies
Healthcare provider profile · identity verified
John L Hunt, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MALDEN, MO · NPI 1508881533
Verified facts
What the public records show
CMS Open Payments records show John L Hunt, M.D. received $52.04 in general payments during 2025 across 3 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 72.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.70 | 72.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.34 | 27.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $37.70 | 2 |
| Food and Beverage | $14.34 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1101 | 153 |
| Alprazolam | Alprazolam | 886 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 614 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 435 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 429 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 408 | 80 |
| Furosemide | Furosemide | 387 | 79 |
| Metformin Hcl | Metformin Hcl | 385 | 72 |
| Omeprazole | Omeprazole | 377 | 67 |
| Lisinopril | Lisinopril | 373 | 79 |
| Gabapentin | Gabapentin | 363 | 59 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 263 | 40 |
| Tramadol Hcl | Tramadol Hcl | 251 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 247 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 210 | 45 |
| Potassium Chloride | Potassium Chloride | 195 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 194 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 52 |
| Losartan Potassium | Losartan Potassium | 185 | 39 |
| Famotidine | Famotidine | 173 | 32 |
| Ezetimibe | Ezetimibe | 165 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 149 | 31 |
| Meloxicam | Meloxicam | 137 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 26 |
| Sertraline Hcl | Sertraline Hcl | 136 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 28 |
| Pregabalin | Pregabalin | 124 | 20 |
| Allopurinol | Allopurinol | 123 | 22 |
| Eliquis | Apixaban | 123 | 25 |
| Trazodone Hcl | Trazodone Hcl | 121 | 20 |
| Diazepam | Diazepam | 115 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 115 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 23 |
| Montelukast Sodium | Montelukast Sodium | 113 | 19 |
| Clonidine Hcl | Clonidine Hcl | 109 | 24 |
| Ibuprofen | Ibuprofen | 108 | 17 |
| Carvedilol | Carvedilol | 106 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 21 |
| Azithromycin | Azithromycin | 102 | 79 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 14 |
| Lorazepam | Lorazepam | 101 | 16 |
| Simvastatin | Simvastatin | 99 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 99 | 19 |
| Januvia | Sitagliptin Phosphate | 98 | 16 |
| Promethazine Hcl | Promethazine Hcl | 97 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 22 |
| Amoxicillin | Amoxicillin | 87 | 56 |
| Clonazepam | Clonazepam | 86 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 22 |
| Glipizide | Glipizide | 82 | 14 |
| Glimepiride | Glimepiride | 81 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 77 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 17 |
| Lovastatin | Lovastatin | 72 | 15 |
| Jardiance | Empagliflozin | 70 | 15 |
| Rybelsus | Semaglutide | 70 | 11 |
| Vascepa | Icosapent Ethyl | 70 | suppressed |
| Prednisone | Prednisone | 69 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | suppressed |
| Verapamil Er | Verapamil Hcl | 64 | 19 |
| Linzess | Linaclotide | 61 | suppressed |
| Spironolactone | Spironolactone | 57 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 54 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 52 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Acyclovir | Acyclovir | 49 | 18 |
| Meclizine Hcl | Meclizine Hcl | 49 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 30 |
| Ozempic | Semaglutide | 48 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 47 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 15 |
| Cefdinir | Cefdinir | 46 | 35 |
| Metformin Hcl Er | Metformin Hcl | 46 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Topiramate | Topiramate | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Estradiol | Estradiol | 39 | suppressed |
| Methocarbamol | Methocarbamol | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 37 | suppressed |
| Nystatin | Nystatin | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 23 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 25 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Naproxen | Naproxen | 33 | 13 |
| Single Use Swab | Alcohol Antiseptic Pads | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 24 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Ssd | Silver Sulfadiazine | 24 | 13 |
| Valsartan | Valsartan | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 17 |
| Verapamil Hcl | Verapamil Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 18 | 17 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Humulin R | Insulin Regular, Human | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $52.04 · 3 records | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error